- Home
- FOLD vs GBTG Comparison
FOLD vs GBTG Comparison
Compare FOLD & GBTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOLD
- GBTG
- Stock Information
- Founded
- FOLD 2002
- GBTG 2014
- Country
- FOLD United States
- GBTG United States
- Employees
- FOLD N/A
- GBTG N/A
- Industry
- FOLD Biotechnology: Pharmaceutical Preparations
- GBTG Computer Software: Prepackaged Software
- Sector
- FOLD Health Care
- GBTG Technology
- Exchange
- FOLD Nasdaq
- GBTG Nasdaq
- Market Cap
- FOLD 2.9B
- GBTG 3.2B
- IPO Year
- FOLD 2007
- GBTG N/A
- Fundamental
- Price
- FOLD $6.32
- GBTG $6.08
- Analyst Decision
- FOLD Strong Buy
- GBTG Strong Buy
- Analyst Count
- FOLD 10
- GBTG 4
- Target Price
- FOLD $26.89
- GBTG $9.63
- AVG Volume (30 Days)
- FOLD 4.2M
- GBTG 947.2K
- Earning Date
- FOLD 07-31-2025
- GBTG 08-05-2025
- Dividend Yield
- FOLD N/A
- GBTG N/A
- EPS Growth
- FOLD N/A
- GBTG N/A
- EPS
- FOLD N/A
- GBTG N/A
- Revenue
- FOLD $571,160,000.00
- GBTG $2,434,000,000.00
- Revenue This Year
- FOLD $19.97
- GBTG $2.77
- Revenue Next Year
- FOLD $22.92
- GBTG $4.42
- P/E Ratio
- FOLD N/A
- GBTG N/A
- Revenue Growth
- FOLD 32.29
- GBTG 4.82
- 52 Week Low
- FOLD $5.51
- GBTG $5.78
- 52 Week High
- FOLD $12.65
- GBTG $9.60
- Technical
- Relative Strength Index (RSI)
- FOLD 55.44
- GBTG 37.69
- Support Level
- FOLD $6.06
- GBTG $6.50
- Resistance Level
- FOLD $6.40
- GBTG $6.87
- Average True Range (ATR)
- FOLD 0.28
- GBTG 0.19
- MACD
- FOLD 0.01
- GBTG -0.03
- Stochastic Oscillator
- FOLD 49.44
- GBTG 4.85
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
About GBTG Global Business Travel Group Inc.
Global Business Travel Group Inc operates as a business-to-business travel platform. It is engaged in providing software and services to manage travel, expenses, and meetings and events for companies of all sizes. The company is engaged in building the marketplace in B2B travel to deliver unrivaled choice, value, and experiences. It also provides business travel solutions, simplified travel management, and business consulting services. Further, The company generates revenue in two ways that involves fees and other revenues relating to processing and servicing travel transactions received from clients and travel suppliers and revenues for the provision of products and professional services not directly related to transactions received from clients, travel suppliers and Network Partners.